ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03836664
Recruitment Status : Completed
First Posted : February 11, 2019
Last Update Posted : February 11, 2019
Sponsor:
Information provided by (Responsible Party):
University of Kansas Medical Center

Brief Summary:
The purpose of this study is to see if Timolol 0.5% ophthalmic solution (Timolol eye drops) are a safe and effective treatment for acute migraine headaches.

Condition or disease Intervention/treatment Phase
Migraine Drug: Timolol Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine
Actual Study Start Date : February 27, 2017
Actual Primary Completion Date : April 14, 2018
Actual Study Completion Date : April 14, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Headache Migraine

Arm Intervention/treatment
Experimental: Group 1: Timolol
Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
Drug: Timolol
Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
Other Name: 0.5% timolol ophthalmic solution

Placebo Comparator: Group 2: Placebo
Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
Drug: Placebo
Placebo is normal saline solution that will be supplied in container matched to Timolol container.




Primary Outcome Measures :
  1. Headache severity [ Time Frame: headache severity at 120 minutes post intervention use ]
    Measure of the change in severity using pain relief scale. Scale will be completed after each migraine over course of participation in study, up to 8 weeks.


Secondary Outcome Measures :
  1. Safety of using Timolol [ Time Frame: 8 weeks ]
    Measured by count of adverse events experienced by study participants

  2. Subject satisfaction with Intervention [ Time Frame: 8 weeks ]
    Measured by patient-reported satisfaction questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of migraine, with or without aura, according to ICHD-2 criteria (Appendix A) for at least 1 year prior to screening; experience an average of 1 to 8 migraines per month.
  • Females must be practicing an effective method of birth control before entry and throughout the study, or be surgically sterile, or be postmenopausal
  • Females of child-bearing potential must have a negative urine pregnancy test
  • Subjects should be able to demonstrate the ability to properly administer study medication
  • Subjects should be able and willing to read and comprehend written instructions and complete the diary information required by the protocol
  • Subjects must be capable, in the opinion of the Investigator, of providing informed consent or assent to participate in the study
  • Subjects (and their legally acceptable representatives, if applicable) must provide an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

  • Inability to distinguish other headaches from migraine
  • Experiences headache of any kind at a frequency greater than or equal to 15 days per month
  • Current use of medication for migraine prophylaxis that has not been stable (no dose adjustment) for 30 days prior to screening
  • Chronic opioid therapy for headaches (> 3 consecutive days in the 30 days prior to screening)
  • Hemiplegic migraine
  • History, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes
  • History of glaucoma and/or current treatment with prescription eye drops
  • History of naso-lacrimal duct ("tear duct problem" to patients) obstruction or surgery for such
  • Active treatment by ophthalmologist or optometrist for any severe ophthalmic disease or problem
  • Any physical problems or co-ordination difficulty or eye avoidance sensitivity ("squeezer") that would preclude proper installation of eye drops in either or both eyes
  • History of uncontrolled asthma, COPD, or reversible airway disease which in the opinion of the investigator would be worsened by the use of beta blockers
  • History of clinically symptomatic bradycardia, congestive heart failure, or hypotension
  • Uncontrolled Diabetes Mellitus
  • Uncontrolled Hyperthyroidism
  • History (within 2 years) of drug or alcohol abuse
  • Systemic disease, which in the opinion of the Investigator, would contraindicate participation
  • History of a neurological or psychiatric condition, which in the opinion of the Investigator would contraindicate participation
  • History of hypersensitivity or intolerance to beta-blockers eye drops
  • Pregnant or lactating women
  • Have taken any investigational medication within 12 weeks before randomization, or are scheduled to receive an investigational drug
  • Subjects, who in opinion of the Investigator, should not be enrolled in the study because of the precautions, warnings or contra-indications sections of the timolol Package Insert

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03836664


Locations
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
University of Kansas Medical Center
Investigators
Principal Investigator: Dipika Aggarwal, MD University of Kansas Medical Center

Responsible Party: University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT03836664     History of Changes
Other Study ID Numbers: STUDY00140465
First Posted: February 11, 2019    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Kansas Medical Center:
Headache
Acute migraine headache

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pharmaceutical Solutions
Ophthalmic Solutions
Timolol
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents